Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: July 8, 2005
Last updated: June 3, 2013
Last verified: June 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)